GLP-1 family
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)
Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021
PMID: 33625476 · DOI: 10.1001/jama.2021.1831
Summary
Randomized clinical trial in 611 adults comparing 68 weeks of once-weekly subcutaneous semaglutide vs placebo, both combined with intensive behavioral therapy and an initial low-calorie diet. Primary endpoint: percent change in body weight.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →GLP-1 SSingle-receptor incretin class agonist studied in incretin-pathway metabolic research.
Guides covering this compound
- How to read a peptide Certificate of AnalysisThe five numbers that actually matter on a peptide COA, what they mean, and the red flags that should make you choose a different supplier.7 min read
- HPLC vs mass spec vs amino acid analysis — what each test provesA practical guide to the three peptide QC methods, what each can prove and disprove, and why a complete QC profile requires all three.5 min read
- Made in the USA, and what that actually meansWhere our peptides are made, how we vet the active ingredient, and why independent per-lot testing matters more than any origin claim.3 min read
- How to evaluate a peptide supplier — a buyer's checklistTwelve questions every research customer should ask a peptide supplier before placing the first order, and what each answer reveals about the vendor's quality posture.4 min read
More GLP-1 family citations